Abstract
Previous studies have shown elevated serum levels of interleukin 6 (IL‐6) and C‐reactive protein (CRP) in patients with pancreatic cancer (PC). The aim of this study was to assess the diagnostic usefulness of pretreatment serum levels of IL‐6 and CRP to differentiate between PC and chronic pancreatitis (CP) patients. Serum levels of CRP, IL‐6, carcinoembryonic antigen (CEA), and carbohydrate antigen 19‐9 (CA 19‐9) were determined in 78 patients with PC before surgery, in 45 patients with CP, and in 70 healthy controls. Serum levels of all the proteins tested were significantly higher in cancer patients when compared with CP and healthy subjects, and increased in more advanced tumor stages. Concentrations of IL‐6 were significantly higher in nonresectable tumors and in patients who died during the 2‐year observation period. Area under receiver operating characteristic curve for IL‐6 was higher than for other substances tested in the differentiation between PC and CP. Cox's univariate analysis revealed serum IL‐6 as a significant prognostic factor of patients' survival. Our findings suggest higher diagnostic usefulness of serum IL‐6 than CRP, CEA, and CA 19‐9 in the diagnosis and prognosis of patients with PC and in the differentiation with CP. J. Clin. Lab. Anal. 24:256–261, 2010. © 2010 Wiley‐Liss, Inc.
Keywords: interleukin 6, C‐reative protein, pancreatic cancer, chronic pancreatitis, tumor markers
REFERENCES
- 1. Carpelan‐Holmstrom M, Nordling S, Pukkala E, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re‐evaluating the date of Finnish Cancer Registry. Gut 2005;54:385–387. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Engelken FJ, Bettschart V, Rahman MQ, Parks RW, Garden OJ. Prognostic factors in the palliation of pancreatic cancer. Eur J Surg Oncol 2003;29:368–373. [DOI] [PubMed] [Google Scholar]
- 3. Krzystek‐Korpacka M, Matusiewicz M, Diakowska D, et al. Acute‐phase response proteins are related to cachexia and accelerated angiogenesis in gastroesophageal cancers. Clin Chem Lab Med 2008;46:359–364. [DOI] [PubMed] [Google Scholar]
- 4. Du Clos TW. Function of C‐reactive protein. Ann Med 2000;32:274–278. [DOI] [PubMed] [Google Scholar]
- 5. Bartsch R, Woehrer S, Raderer M, Hejna M. Serum interleukin‐6 levels in patients with gastric MALT lymphoma compared to gastric and pancreatic cancer. Anticancer Res 2006;26:3187–3190. [PubMed] [Google Scholar]
- 6. Bellone G, Smirne C, Mauri FA, et al. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: Implications for survival. Cancer Immunol Immunother 2006;55:684–698. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Nikiteas NI, Tzanakis N, Gazouli M, et al. Serum IL‐6, TNF alpha and CRP levels in Greek colorectal cancer patients: Prognostic implications. World J Gastroenterol 2005;11:1639–1643. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Müller MW, Friess H, Köninger J, et al. Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas. Am J Surg 2008;195:221–228. [DOI] [PubMed] [Google Scholar]
- 9. Groblewska M, Mroczko B, Wereszczyńska‐Siemiątkowska U, et al. Serum interleukin 6 (IL‐6) and C‐reactive protein (CRP) levels in colorectal adenoma and cancer patients. Clin Chem Lab Med 2008;46:1423–1428. [DOI] [PubMed] [Google Scholar]
- 10. Talar‐Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz‐Makowska H, Kulig A, Malecka‐Panas E. Clinical significance of interleukin‐6 (IL‐6) gene polymorphism and IL‐6 serum level in pancreatic adenocarcinoma and chronic pancreatitis. Dig Dis Sci 2009;54:683–689. [DOI] [PubMed] [Google Scholar]
- 11. Wigmore SJ, Todorov PT, Barber MD, Ross JA, Tisdale MJ, Fearon KC. Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor. Br J Surg 2000;87:53–58. [DOI] [PubMed] [Google Scholar]
- 12. Tingstedt B, Johansson P, Andersson B, et al. Predictive factors in pancreatic ductal adenocarcinoma: Role of the inflammatory response. Scand J Gastroenterol 2007;42:754–759. [DOI] [PubMed] [Google Scholar]
- 13. Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R. Cytokines in pancreatic carcinoma: Correlation with phenotypic characteristics and prognosis. Cancer 2004;102:2727–2736. [DOI] [PubMed] [Google Scholar]
- 14. Jass JR, Sobin LH. 1989. WHO International Histological Classification of Tumors. Histological typing of Intestinal Tumors. New York: Springer. [Google Scholar]
- 15. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5–26. [DOI] [PubMed] [Google Scholar]
- 16. Ueno H, Okada S, Okusaka T, Ikeda M. Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 2000;59:296–301. [DOI] [PubMed] [Google Scholar]
- 17. Sohn TA, Lillemoe KD. Surgical palliation of pancreatic cancer. Adv Surg 2000;34:249–271. [PubMed] [Google Scholar]
- 18. Barber MD, Fearon KC, Ross JA. Relationship of serum levels of interleukin‐6, soluble interleukin‐6 receptor and tumour necrosis factor receptors to the acute‐phase protein response in advanced pancreatic cancer. Clin Sci (Lond) 1999;96:83–87. [PubMed] [Google Scholar]
- 19. Okada S, Okusaka T, Ishii H, et al. Elevated serum interleukin‐6 levels in patients with pancreatic cancer. Jpn J Clin Oncol 1998;28:12–15. [DOI] [PubMed] [Google Scholar]
- 20. Wenger FA, Jacobi CA, Zieren J, Döcke W, Volk HD, Müller JM. Tumor size and lymph‐node status in pancreatic carcinoma—Is there a correlation to the preoperative immune function? Langenbecks Arch Surg 1999;384:473–478. [DOI] [PubMed] [Google Scholar]
- 21. Groblewska M, Mroczko B, Wereszczyńska‐Siemiatkowska U, Myśliwiec P, Kedra B, Szmitkowski M. Serum levels of granulocyte colony‐stimulating factor (G‐CSF) and macrophage colony‐stimulating factor (M‐CSF) in pancreatic cancer patients. Clin Chem Lab Med 2007;45:30–34. [DOI] [PubMed] [Google Scholar]